STOK250117C10000
- 0.10
- 0.000.00%
Stoke Therapeutics Newsroom
Shareholders Can't Ignore US$523k Of Sales By Stoke Therapeutics Insiders
Is It a Good Idea to Invest in Stoke Therapeutics Stock Now?
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24
Stoke Therapeutics Negative Reaction After STK-001 Update Overdone, Says Chardan
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $22
Stoke Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk
Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial
Stoke Therapeutics Finalizes EMPEROR Study Program With Regulatory Agencies
Express News | Stoke Therapeutics : FDA Breakthrough Therapy Designation Positions Zorevunersen on Efficient Development Path; Plans to Start Phase 3 in Mid-2025
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
Stoke Therapeutics(STOK.US) 10% Shareholder Sells US$23 Million in Common Stock
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Express News | Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 23.18 Million in Common Stocks
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Initiated at Buy by Chardan Capital